Amicus Therapeutics Statistics
Share Statistics
Amicus Therapeutics has 298.81M shares outstanding. The number of shares has increased by 3.3% in one year.
| Shares Outstanding | 298.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 291.26M |
| Failed to Deliver (FTD) Shares | 2.93K |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 19.90M, so 6.66% of the outstanding shares have been sold short.
| Short Interest | 19.90M |
| Short % of Shares Out | 6.66% |
| Short % of Float | 6.83% |
| Short Ratio (days to cover) | 8.35 |
Valuation Ratios
The PE ratio is -27.63 and the forward PE ratio is 65.56.
| PE Ratio | -27.63 |
| Forward PE | 65.56 |
| PS Ratio | 10.49 |
| Forward PS | 4.4 |
| PB Ratio | 26.15 |
| P/FCF Ratio | -54.73 |
| PEG Ratio | n/a |
Enterprise Valuation
Amicus Therapeutics Inc. has an Enterprise Value (EV) of 4.39B.
| EV / Earnings | -28.94 |
| EV / Sales | 10.98 |
| EV / EBITDA | -47.64 |
| EV / EBIT | -59.68 |
| EV / FCF | -57.32 |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 2.47.
| Current Ratio | 2.88 |
| Quick Ratio | 2.52 |
| Debt / Equity | 2.47 |
| Total Debt / Capitalization | 71.21 |
| Cash Flow / Debt | -0.17 |
| Interest Coverage | -1.47 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -12.26%.
| Return on Equity (ROE) | -0.95% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -12.26% |
| Revenue Per Employee | 798.71K |
| Profits Per Employee | -303.17K |
| Employee Count | 500 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 0.63 |
Taxes
| Income Tax | 1.48M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -26.42% in the last 52 weeks. The beta is 0.67, so Amicus Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -26.42% |
| 50-Day Moving Average | 10.56 |
| 200-Day Moving Average | 10.73 |
| Relative Strength Index (RSI) | 49.8 |
| Average Volume (20 Days) | 2.59M |
Income Statement
In the last 12 months, Amicus Therapeutics had revenue of $399.36M and earned -$151.58M in profits. Earnings per share was $-0.51.
| Revenue | 399.36M |
| Gross Profit | 362.03M |
| Operating Income | -73.49M |
| Net Income | -151.58M |
| EBITDA | -92.08M |
| EBIT | -73.49M |
| Earnings Per Share (EPS) | -0.51 |
Balance Sheet
The company has $246.99M in cash and $445.06M in debt, giving a net cash position of -$198.06M.
| Cash & Cash Equivalents | 246.99M |
| Total Debt | 445.06M |
| Net Cash | -198.06M |
| Retained Earnings | -2.68B |
| Total Assets | 786.56M |
| Working Capital | 340.34M |
Cash Flow
In the last 12 months, operating cash flow was -$69.09M and capital expenditures -$7.44M, giving a free cash flow of -$76.53M.
| Operating Cash Flow | -69.09M |
| Capital Expenditures | -7.44M |
| Free Cash Flow | -76.53M |
| FCF Per Share | -0.26 |
Margins
Gross margin is 90.65%, with operating and profit margins of -18.4% and -37.96%.
| Gross Margin | 90.65% |
| Operating Margin | -18.4% |
| Pretax Margin | -37.59% |
| Profit Margin | -37.96% |
| EBITDA Margin | -23.06% |
| EBIT Margin | -18.4% |
| FCF Margin | -19.16% |
Dividends & Yields
FOLD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.45% |
| FCF Yield | -2.74% |
Analyst Forecast
The average price target for FOLD is $17, which is 81.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 81.6% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -0.84 |
| Piotroski F-Score | 5 |